Recently, a Chinese court reversed the invalidation decision of the State Intellectual Property Office on one of Pfizer's Chinese patents on Viagra. Leading IP experts will give a comprehensive overview of the history and trends of IP system, share their experience of IP protection and enforcement, address IP concerns associated with biopharmaceutical companies investing in China, and discuss solutions and strategies to manage IP risks and combat IP infringement/piracy in China.



Objectives:

Gain a firsthand, balanced understanding of IP enforcement in China, ranging from IP policy makers to global IP practitioners.

Improve knowledge of the IP environment in China to help people make decisions about commercialization, investment and IP protection in China.

Understand how to manage IP risks and combat IP infringement or piracy in China.